159 related articles for article (PubMed ID: 30560478)
21. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
Prakash A; Babu KS; Morjaria JB
Int J Chron Obstruct Pulmon Dis; 2015; 10():111-23. PubMed ID: 25609944
[TBL] [Abstract][Full Text] [Related]
22. Clinical use of aclidinium in patients with COPD.
Reid DJ; Carlson AA
Int J Chron Obstruct Pulmon Dis; 2014; 9():369-79. PubMed ID: 24812502
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues.
Hegde SS; Pulido-Rios MT; Luttmann MA; Foley JJ; Hunsberger GE; Steinfeld T; Lee T; Ji Y; Mammen MM; Jasper JR
Pharmacol Res Perspect; 2018 Jun; 6(3):e00400. PubMed ID: 29736245
[TBL] [Abstract][Full Text] [Related]
24. Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study.
Kerwin EM; Donohue JF; Ferguson GT; Ganapathy V; Ozol-Godfrey A; Rajagopalan K
J Aerosol Med Pulm Drug Deliv; 2019 Feb; 32(1):24-33. PubMed ID: 30457433
[TBL] [Abstract][Full Text] [Related]
25. Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD.
Albertson TE; Bowman WS; Harper RW; Godbout RM; Murin S
Int J Chron Obstruct Pulmon Dis; 2019; 14():1251-1265. PubMed ID: 31239659
[TBL] [Abstract][Full Text] [Related]
26. ▾Glycopyrronium for COPD.
Drug Ther Bull; 2013 Jun; 51(6):66-8. PubMed ID: 23744364
[TBL] [Abstract][Full Text] [Related]
27. Seebri Neohaler and Utibron Neohaler for COPD.
Med Lett Drugs Ther; 2016 Mar; 58(1491):39-41. PubMed ID: 27027687
[No Abstract] [Full Text] [Related]
28. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
Horita N; Kaneko T
Int J Chron Obstruct Pulmon Dis; 2015; 10():813-22. PubMed ID: 25960646
[TBL] [Abstract][Full Text] [Related]
29. Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease.
Pleasants RA
Ann Pharmacother; 2019 Mar; 53(3):285-293. PubMed ID: 30175596
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US.
Rajagopalan K; Bloudek L; Marvel J; Dembek C; Kavati A
Int J Chron Obstruct Pulmon Dis; 2018; 13():3867-3877. PubMed ID: 30568438
[TBL] [Abstract][Full Text] [Related]
31. Nebulized glycopyrrolate (Lonhala Magnair) for COPD.
Med Lett Drugs Ther; 2018 Apr; 60(1543):72. PubMed ID: 29667949
[No Abstract] [Full Text] [Related]
32. Lung deposition of inhaled once-daily long-acting muscarinic antagonists
Crater GD; Johnson K; Ward J; Backer J
Ther Adv Respir Dis; 2022; 16():17534666221077561. PubMed ID: 35234085
[TBL] [Abstract][Full Text] [Related]
33. Olodaterol: first global approval.
Gibb A; Yang LP
Drugs; 2013 Nov; 73(16):1841-6. PubMed ID: 24158691
[TBL] [Abstract][Full Text] [Related]
34. Exacerbation recovery patterns in newly diagnosed or maintenance treatment-naïve patients with COPD: secondary analyses of TICARI 1 trial data.
Mannino DM; Clerisme-Beaty EM; Franceschina J; Ting N; Leidy NK
Int J Chron Obstruct Pulmon Dis; 2018; 13():1515-1525. PubMed ID: 29785101
[TBL] [Abstract][Full Text] [Related]
35. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.
Ulrik CS
Int J Chron Obstruct Pulmon Dis; 2014; 9():331-8. PubMed ID: 24729699
[TBL] [Abstract][Full Text] [Related]
36. Population Pharmacokinetics of Revefenacin in Patients with Chronic Obstructive Pulmonary Disease.
Lo A; Borin MT; Bourdet DL
Clin Pharmacokinet; 2021 Mar; 60(3):391-401. PubMed ID: 33124005
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
LaForce C; Feldman G; Spangenthal S; Eckert JH; Henley M; Patalano F; D'Andrea P
Int J Chron Obstruct Pulmon Dis; 2016; 11():1233-43. PubMed ID: 27354782
[TBL] [Abstract][Full Text] [Related]
38. An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD.
Singh D; D'Urzo AD; Donohue JF; Kerwin EM; Molins E; Chuecos F; Ribera A; Jarreta D
Int J Chron Obstruct Pulmon Dis; 2019; 14():2835-2848. PubMed ID: 31827323
[TBL] [Abstract][Full Text] [Related]
39. Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator.
Singh D; Balaguer V; Astbury C; Wählby-Hamrén U; Jimenez E; Seoane B; Villarroel C; Lei A; Aggarwal A; Psallidas I
Respir Res; 2020 Sep; 21(Suppl 1):102. PubMed ID: 32907566
[TBL] [Abstract][Full Text] [Related]
40. Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit.
Ulrik CS
Int J Chron Obstruct Pulmon Dis; 2012; 7():673-8. PubMed ID: 23055716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]